Change Notification UK National Blood Services  No. 22 - 2017

Radiation Therapy

These changes apply to the individual Tissue and Cells Donor Selection Guidelines as stated below.


Please modify “Discretionary”, “See if Relevant”, “Additional Information” and “Reason for Change” as follows:

Discretionary

a) If fully recovered and is acceptable according to immunosuppression advice, accept.
b) If for basal cell carcinoma or ductal carcinoma in situ of the breast, all treatment has been completed, the donor has been discharged from follow up and is eligible under the Malignancy Guideline, accept.

See if Relevant

Basal Cell Carcinoma
Malignancy
Immunosuppression

Additional Information

Radiation therapy is sometimes used for non-malignant conditions, particularly for some skin conditions. It is often used as a substitute for other treatments that work by suppressing the immune system such as high dose steroids and cytotoxic drugs. More information is likely to be required before a decision can be made as to if an individual can donate. This why a referral to a ‘Designated Medical Officer’ is required.

Reason for Change

Additional discretionary acceptance for basal cell carcinomas and ductal carcinoma in situ of the breast. A link had been added to autoimmune disease, and additional information has been added.
2. Tissue Donor Selection Guidelines – Live Donors

Please modify “Discretionary”, “See if Relevant”, “Additional Information” and “Reason for Change” as follows:

Discretionary
a) If fully recovered and is acceptable according to immunosuppression advice, accept.
b) If for basal cell carcinoma or ductal carcinoma in situ of the breast, all treatment has been completed, the donor has been discharged from follow up and is eligible under the Malignancy Guideline, accept.

See if Relevant
Basal Cell Carcinoma
Malignancy
Immunosuppression

Additional Information
Radiation therapy is sometimes used for non-malignant conditions, particularly for some skin conditions. It is often used as a substitute for other treatments that work by suppressing the immune system such as high dose steroids and cytotoxic drugs. More information is likely to be required before a decision can be made as to if an individual can donate. This why a referral to a ‘Designated Medical Officer’ is required.

Reason for Change
Additional discretionary acceptance for basal cell carcinomas and ductal carcinoma in situ of the breast. A link had been added to autoimmune disease, and additional information has been added.

3. Tissue Donor Selection Guidelines – Deceased Donors

Please modify “Discretionary”, “See if Relevant”, “Additional Information” and “Reason for Change” as follows:

Discretionary
a) Eyes:
   If related to malignancy and the eyes were not included in the field of irradiation, see Malignancy.

   b) If fully recovered and is acceptable according to immunosuppression advice, accept.

   c) If for basal cell carcinoma or ductal carcinoma in situ of the breast, all treatment has been completed, the donor has been discharged from follow up and is eligible under the Malignancy Guideline, accept.

\Continued
See if Relevant

Basal Cell Carcinoma
Malignancy
Immunosuppression

Additional Information

Radiation therapy is sometimes used for non-malignant conditions, particularly for some skin conditions. It is often used as a substitute for other treatments that work by suppressing the immune system such as high dose steroids and cytotoxic drugs. More information is likely to be required before a decision can be made as to if an individual can donate. This why a referral to a ‘Designated Medical Officer’ is required.

Reason for Change

Additional discretionary acceptance for basal cell carcinomas and ductal carcinoma in situ of the breast. A link had been added to autoimmune disease, and additional information has been added.

Dr Sheila MacLennan
Professional Director - Joint UKBTS Professional Advisory Committee

Direct Dial: (0113) 820 8638  sheila.maclennan@nhsbt.nhs.uk